Claudin 18.2 as a novel therapeutic target

Nature Reviews Clinical Oncology, Published online: 19 March 2024; doi:10.1038/s41571-024-00874-2The development and successful phase III testing of the anti-claudin 18.2 antibody zolbetuximab has provided a novel targeted therapy for the 30–40% of patients with strongly claudin 18.2-positive gastric cancers. Furthermore, the development of an effective targeted therapy for a target that does not have a driver role in cancer development provides a novel drug development paradigm. In this Review, the authors describe the development of claudin 18.2-targeted therapies, including zolbetuximab, as well as novel therapies, including chimeric antigen receptor (CAR) T cells, antibody–drug conjugates and bispecific antibodies, all of which have the potential to expand the number of patients who can derive benefit from claudin 18.2-targeted therapies in the near future.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research